Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: Influence of nutritional folate status on toxicity

Journal of Chemotherapy

Volumn 19, Issue 6, 2007, Pages 744-749

  Alvarez Cabellos, R ^a   Garcia Carbonero, R ^a,c   Garcia Lacalle, C ^a   Gomez, P ^b   Tercero, A ^a   Sanchez, D ^a   Paz Ares, L ^b  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Fluoropyrimidines; Folate; Gastrointestinal cancer; Homocysteine; Toxicity; Vitamin B12

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLIC ACID DEFICIENCY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUTRITIONAL STATUS; PANCREAS CANCER; PROGNOSIS; STOMACH CANCER; THROMBOCYTOPENIA; VITAMIN BLOOD LEVEL; VOMITING;

EID: 38949134103     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.6.744     Document Type: Article

References (20)

1. Magnus EM. Folate activity in serum and red cells of patients with cancer. Cancer Res 1967; 27(3): 490-497.
2. Clamon GH, Feld R, Evans WK et al. Serum folate and vitamin B12 levels in patients with small cell lung cancer. Cancer 1984; 53(2): 306-310.
3. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6(10): 1653-1664.
4. Thirion P, Michiels S, Pignon JP et al. Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated metaanalysis. J Clin Oncol 2004; 22(18): 3766-3775.
5. Branda RF, Nigels E, Lafayette AR, Hacker M. Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 1998; 92(7): 2471-2476.
6. Raghunathan K, Schmitz JC, Priest DG. Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice. Biochem Pharmacol 1997; 53(8): 1197-1202.
7. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994; 96(3):239-246.
8. Neoptolemos JP, Stocken DD, Friess H et al; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350(12): 1200-1210.
9. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10): 725-730.
10. Cunningham D, Allum WH, Stenning SP et al, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11-20.
11. Oken MM, Creech RH, Tormey DC et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
12. http://www.ctep.nci.nih.gov
13. Tzortzatou F. Reversibility of the toxicity of methotrexate by dihydrofolate in mice. Clin Exp Pharmacol Physiol 1979; 6(5): 581-583.
14. Bertino JR, Levitt M, McCullough JL, Chabner B. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion. Ann N Y Acad Sci 1971; 186: 486-495.
15. Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999; 17(5):1589-94.
16. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002; 29(2 Suppl 5): 3-7.
17. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1(7): 545-552.
18. Niyikiza C, Hanauske AR, Rusthoven JJ et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002; 29(6 Suppl 18): 24-29.
19. Sharma R, Rivory L, Beale P et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006; 94(7): 964-968.
20. [No authors listed] Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16(11): 3537-3541.